SBI Okasan Asset Management Co.Ltd. trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 35.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,705 shares of the medical device company’s stock after selling 9,800 shares during the period. SBI Okasan Asset Management Co.Ltd.’s holdings in DexCom were worth $1,534,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the company. Latitude Advisors LLC purchased a new stake in DexCom in the third quarter worth approximately $32,000. Hilton Head Capital Partners LLC raised its stake in shares of DexCom by 242.3% during the third quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after acquiring an additional 269 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after acquiring an additional 152 shares in the last quarter. GK Wealth Management LLC purchased a new position in shares of DexCom during the third quarter worth approximately $35,000. Finally, Signature Equity Partners LLC lifted its holdings in shares of DexCom by 97.3% in the 3rd quarter. Signature Equity Partners LLC now owns 436 shares of the medical device company’s stock worth $38,000 after acquiring an additional 215 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on DXCM. Argus upped their price objective on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $97.00 target price (up from $94.00) on shares of DexCom in a report on Friday, October 30th. Citigroup lifted their target price on shares of DexCom from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Canaccord Genuity Group lifted their target price on shares of DexCom from $90.00 to $97.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $95.50.
View Our Latest Stock Report on DexCom
Insider Buying and Selling
In related news, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the transaction, the executive vice president directly owned 120,913 shares of the company’s stock, valued at $9,506,180.06. The trade was a 2.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 22,822 shares of company stock worth $1,920,193. 0.28% of the stock is owned by company insiders.
DexCom Trading Down 2.1%
Shares of DXCM stock opened at $81.61 on Tuesday. The business has a 50-day moving average of $84.17 and a 200 day moving average of $75.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40. DexCom, Inc. has a 1-year low of $56.72 and a 1-year high of $92.59. The stock has a market capitalization of $30.44 billion, a PE ratio of 32.00, a P/E/G ratio of 1.34 and a beta of 1.45.
DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.68 earnings per share for the current year.
DexCom Company Profile
DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.
Read More
- Five stocks we like better than DexCom
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
